In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine

npj Vaccines

Volumn 1, Issue , 2016, Pages

  Muthumani, Karuppiah ^a   Griffin, Bryan D ^b,c   Agarwal, Sangya ^a   Kudchodkar, Sagar B ^a   Reuschel, Emma L ^a   Choi, Hyeree ^a   Kraynyak, Kimberly A ^d   Duperret, Elizabeth K ^a   Keaton, Amelia Anne ^e   Chung, Christopher ^a   Kim, Yinho K ^a   Booth, Stephanie A ^b,c   Racine, Trina ^b,c   Yan, Jian ^d   Morrow, Matthew P ^d   Jiang, Jingjing ^d   Lee, Brian ^d   Ramos, Stephanie ^d   Broderick, Kate E ^d   Reed, Charles C ^d   Khan, Amir S ^d   Humeau, Laurent ^d   Ugen, Kenneth E ^f   Park, Young K ^g   Maslow, Joel N ^g   Sardesai, Niranjan Y ^d   Joseph Kim, J ^d   Kobinger, Gary P ^b,c,h   Weiner, David B ^a   more..

^a WISTAR INSTITUTE   (United States)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d Inovio Pharmaceuticals   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

^g GeneOne Life Science Inc   (South Korea)

^h LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85041942761     PISSN: None     EISSN: 20590105     Source Type: Journal    
DOI: 10.1038/npjvaccines.2016.21     Document Type: Article

References (29)

1. Birbeck, G. L. Zika virus: what the neurologist wants to know. Neurology 86, 1272-1274 (2016).
2. Cao-Lormeau, V. M. et al. Zika virus, French polynesia, South pacific, 2013. Emerg. Infect. Dis. 20, 1085-1086 (2014).
3. Weaver, S. C. et al. Zika Virus: history, emergence, biology, and prospects for control. Antiviral Res. 130, 69-80 (2016).
4. Duffy, M. R. et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N. Engl. J. Med. 360, 2536-2543 (2009).
5. Ventura, C. V., Maia, M., Bravo-Filho, V., Gois, A. L. &Belfort, R. Jr. Zika virus in Brazil and macular atrophy in a child with microcephaly. Lancet 387, 228 (2016).
6. Rubin, E. J., Greene, M. F. &Baden, L. R. Zika virus and microcephaly. N. Engl. J. Med. 374, 984-985 (2016).
7. Roa, M. Zika virus outbreak: reproductive health and rights in Latin America. Lancet 387, 843 (2016).
8. Samarasekera, U. &Triunfol, M. Concern over Zika virus grips the world. Lancet 387, 521-524 (2016).
9. Yakob, L. &Walker, T. Zika virus outbreak in the Americas: the need for novel mosquito control methods. Lancet Glob. Health 4, e148-e149 (2016).
10. Cao-Lormeau, V. M. et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 387, 1531-1539 (2016).
11. Mlakar, J. et al. Zika virus associated with microcephaly. N. Engl. J. Med. 374, 951-958 (2016).
12. Check Hayden, E. Proving Zika link to birth defects poses huge challenge. Nature 530, 142-143 (2016).
13. Butler, D. Zika virus: Brazil's surge in small-headed babies questioned by report. Nature 530, 13-14 (2016).
14. Fauci, A. S. &Morens, D. M. Zika virus in the Americas-yet another arbovirus threat. N. Engl. J. Med. 374, 601-604 (2016).
15. Rouvinski, A. et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520, 109-113 (2015).
16. Davis, B. S. et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J. Virol. 75, 4040-4047 (2001).
17. Rossi, S. L. et al. Characterization of a novel murine model to study Zika virus. Am. J. Trop. Med. Hyg, 94, 1362-1369 (2016).
18. Lazear, H. M. et al. A mouse model of Zika virus pathogenesis. Cell Host Microbe 19, 720-730 (2016).
19. Hutnick, N. A. et al. Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses. Hum. Gene Ther. 23, 943-950 (2012).
20. Broderick, K. E. et al. Optimized in vivo transfer of small interfering RNA targeting dermal tissue using in vivo surface electroporation. Mol. Ther. Nucleic Acids 1, e11 (2012).
21. Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature 536, 474-478 (2016).
22. Abbink, P. et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353, 1129-1132 (2016).
23. Trimble, C. L. et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 386, 2078-2088 (2015).
24. Barba-Spaeth, G. et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 536, 48-53 (2016).
25. Muthumani, K. et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci. Transl. Med. 7, 301ra132 (2015).
26. Flingai, S. et al. Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy. Sci. Rep. 5, 12616 (2015).
27. Frey, A., Di Canzio, J. &Zurakowski, D. A statistically defined endpoint titer determination method for immunoassays. J. Immunol. Methods 221, 35-41 (1998).
28. Sun, W. et al. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. J. Infect. Dis. 193, 1658-1665 (2006).
29. Lanciotti, R. S. et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg. Infect. Dis. 14, 1232-1239 (2008).